Micthera is a bio-research firm focused on developing microbial-derived therapeutics specifically for prostate cancer treatment. The company provides medical organizations with targeted, effective solutions to improve patient outcomes in prostate cancer care.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Prostate cancer remains a significant health challenge, requiring targeted and effective therapeutic interventions to improve patient outcomes. Current treatment options may have limitations in efficacy or tolerability, highlighting the need for novel approaches.
Solution
Micthera is a bio-research company focused on the discovery and development of microbial-derived therapeutics for the treatment of prostate cancer. The company leverages the unique properties of microbial compounds to create targeted therapies designed to selectively target and eliminate prostate cancer cells. By harnessing the power of the microbiome, Micthera aims to provide medical organizations with innovative solutions that enhance treatment efficacy and minimize adverse effects for patients battling prostate cancer.
Target Audience
Micthera's primary customers are medical organizations, including hospitals, cancer centers, and research institutions, involved in prostate cancer treatment and research.
Features
- Development of microbial-derived compounds with selective cytotoxicity against prostate cancer cells
- Preclinical research evaluating the efficacy and safety of novel therapeutic candidates
- Targeted drug delivery strategies to maximize therapeutic impact and minimize off-target effects
- Identification and characterization of novel microbial metabolites with anti-cancer properties